Notice2026-11926
Government Owned Inventions Available for License: Fluorophthalimides as Anti-Inflammatory Agents for Systemic and Neurodegenerative Disorders
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 15, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 114 (Monday, June 15, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 114 (Monday, June 15, 2026)]
[Notices]
[Pages 35991-35992]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-11926]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for License:
Fluorophthalimides as Anti-Inflammatory Agents for Systemic and
Neurodegenerative Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging (NIA) seeks research co-
development partners and/or licensees for the pre-clinical and clinical
development of the compounds as anti-inflammatory therapeutics for
systemic and neurodegenerative disorders.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this license
opportunity should be directed to: Nikki Guyton, Ph.D., Unit
Supervisor, NCI, Technology Transfer Center, Email:
[[Page 35992]]
<a href="/cdn-cgi/l/email-protection#50372529243f3e3e103e39387e373f26"><span class="__cf_email__" data-cfemail="7a1d0f030e1514143a141312541d150c">[email protected]</span></a> or Phone: 240-276-5493.
SUPPLEMENTARY INFORMATION: Numerous systemic, as well as neurological
disorders, have a hallmark inflammatory element that can drive disease
progression. However, the use of currently available anti-inflammatory
agents have failed to demonstrate efficacy as potential treatment for
systemic and neurological disorders in clinical trials.
The immunomodulatory imide drug (IMiD) thalidomide exerts anti-
inflammatory effects through inhibition of tumor necrosis factor-alpha
(TNF-[alpha]), which is a master regulator of the inflammatory
response. Researchers at the National Institute on Aging (NIA) have
synthesized novel thalidomide analogs possessing potent anti-
inflammatory actions but, importantly, hinder the cerebon binding that
associated with the adverse teratogenic actions of classic IMiDs. This
invention has potential to be developed as therapeutics for a variety
of systemic and neurological disorders including inflammatory
disorders, autoim.
``This Notice is in accordance with 37 CFR 404.4 Authority to grant
licenses.''
NIH Reference Number: E-151-2022.
Related Technologies: E-045-2012-0; E-208-2015-0.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology [verbar] Neurology.
Development Stage: Pre-clinical (in vivo validation).
Patent Information: US Nonprovisional Patent Application, US 19/
102,830, filed on February 2, 2025. Status: Pending.
Publication: Lecca D, et al. Novel, thalidomide-like, non-cereblon
binding drug etrafluorobornylphthalimide mitigates inflammation and
brain injury. (PMID 36872339).
Potential Commercial Applications:
<bullet> Neurodegenerative diseases.
<bullet> Inflammatory disorders.
<bullet> Autoimmune disorders.
<bullet> Viral infections.
<bullet> Cancer.
Competitive Advantages:
<bullet> More potent anti-inflammatory properties.
<bullet> Potentially clinically safer than classic IMiDs by lower
risk of fetal malformations.
<bullet> Potential to treat a wide range of significant unmet
medical needs.
Dated: June 10, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2026-11926 Filed 6-12-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 15, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.